Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

37 Lawmakers Urge Acting Medicare Chief To Pull Trigger On MCIT Breakthrough Rule

Executive Summary

The US House Democrats signed a letter asking acting CMS administrator Liz Richter to put the Medicare Coverage for Innovative Technology program into place as soon as possible.

You may also be interested in...



CMS Kicks Can Down Road By Pushing MCIT Breakthrough Devices Rule To Dec. 15. Here’s Why

In a move that will undoubtedly ruffle industry feathers, the US Medicare agency on 14 May issued a final rule that moves implementation of the Medicare Coverage of Innovative Technology rule to the end of the year.

CMS Pauses The Clock On Implementing Highly Anticipated Medical Device Reimbursement Rule

The rule was set to go into effect 15 March, but the government is delaying it for at least two months to discuss the resources needed for the payments – and whether they’re the right policy to start with.

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel